LU67546A1 - - Google Patents

Info

Publication number
LU67546A1
LU67546A1 LU67546A LU67546DA LU67546A1 LU 67546 A1 LU67546 A1 LU 67546A1 LU 67546 A LU67546 A LU 67546A LU 67546D A LU67546D A LU 67546DA LU 67546 A1 LU67546 A1 LU 67546A1
Authority
LU
Luxembourg
Application number
LU67546A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LU67546A1 publication Critical patent/LU67546A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0007Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
    • C07J5/0015Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • C07J7/0085Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Steroid Compounds (AREA)
LU67546A 1972-05-05 1973-05-04 LU67546A1 (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2114272A GB1430942A (en) 1972-05-05 1972-05-05 21-substituted 3alpha-hydroxy pregnanes

Publications (1)

Publication Number Publication Date
LU67546A1 true LU67546A1 (en:Method) 1973-07-13

Family

ID=10157915

Family Applications (1)

Application Number Title Priority Date Filing Date
LU67546A LU67546A1 (en:Method) 1972-05-05 1973-05-04

Country Status (16)

Country Link
JP (1) JPS4961150A (en:Method)
AT (1) AT355232B (en:Method)
AU (1) AU475168B2 (en:Method)
BE (1) BE799102A (en:Method)
CA (1) CA1013341A (en:Method)
CH (1) CH617710A5 (en:Method)
DE (1) DE2322532A1 (en:Method)
ES (1) ES414411A1 (en:Method)
FR (1) FR2183792B1 (en:Method)
GB (1) GB1430942A (en:Method)
IE (1) IE37596B1 (en:Method)
IL (1) IL42196A (en:Method)
LU (1) LU67546A1 (en:Method)
NL (1) NL7306234A (en:Method)
SE (1) SE400771B (en:Method)
ZA (1) ZA733035B (en:Method)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
ES2296594T3 (es) * 1994-02-14 2008-05-01 Euro-Celtique S.A. Androstanos y pregnanos para la modulacion alosterica del receptor de gaba.
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
JP4915427B2 (ja) * 2009-03-30 2012-04-11 ブラザー工業株式会社 液体供給ジョイント、これを使用した液体吐出ヘッド及び記録装置
CN104136452A (zh) 2011-10-14 2014-11-05 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
RU2681835C2 (ru) 2012-01-23 2019-03-13 Сейдж Терапьютикс, Инк. Лекарственные формы нейроактивных стероидов и способы лечения нарушений цнс
AU2013305767B2 (en) 2012-08-21 2018-05-24 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
LT2986624T (lt) 2013-04-17 2020-07-10 Sage Therapeutics, Inc. Neuroaktyvūs 9-nor steroidai, skirti gydymo metodams
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
PL3498725T3 (pl) 2013-04-17 2021-11-08 Sage Therapeutics, Inc. 19-Nor C3,3-dipodstawiony C21-N-pirazolilo-steroid do zastosowania w terapii
RS61733B1 (sr) 2013-07-19 2021-05-31 Sage Therapeutics Inc Neuroaktivni steroidi, njihove kompozicije i upotrebe
WO2015027227A1 (en) 2013-08-23 2015-02-26 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
RS60642B1 (sr) 2014-10-16 2020-09-30 Sage Therapeutics Inc Kompozicije i postupci za lečenje poremećaja cns-a
CN117024502A (zh) 2014-10-16 2023-11-10 萨奇治疗股份有限公司 靶向cns障碍的组合物和方法
JP6893173B2 (ja) 2014-11-27 2021-06-23 セージ セラピューティクス, インコーポレイテッド Cns障害を処置するための組成物および方法
PT3250210T (pt) 2015-01-26 2021-03-26 Sage Therapeutics Inc Composições e métodos para o tratamento de distúrbios do snc
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
US20200306265A1 (en) 2016-03-08 2020-10-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
JP7065825B2 (ja) 2016-07-11 2022-05-12 セージ セラピューティクス, インコーポレイテッド C7、c12、およびc16置換神経刺激性ステロイドおよびそれらの使用方法
WO2020243488A1 (en) 2019-05-31 2020-12-03 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1346292A (fr) * 1962-09-14 1963-12-20 Roussel Uclaf Nouveau procédé de préparation des 21-amino stéroïdes
US3144446A (en) * 1963-12-20 1964-08-11 Upjohn Co Mono and bis nu-(3alpha, 17alpha-dihydroxy-11, 20-dioxo-5beta-pregnan-21-yl) quaternary ammonium salts of triethylenediamine

Also Published As

Publication number Publication date
ATA395173A (de) 1979-07-15
BE799102A (fr) 1973-11-05
FR2183792B1 (en:Method) 1977-07-15
GB1430942A (en) 1976-04-07
CH617710A5 (en) 1980-06-13
AT355232B (de) 1980-02-25
IL42196A (en) 1978-10-31
AU5528473A (en) 1974-11-07
JPS4961150A (en:Method) 1974-06-13
IE37596L (en) 1973-11-05
SE400771B (sv) 1978-04-10
NL7306234A (en:Method) 1973-11-07
FR2183792A1 (en:Method) 1973-12-21
AU475168B2 (en) 1976-08-12
ZA733035B (en) 1974-04-24
CA1013341A (en) 1977-07-05
IL42196A0 (en) 1973-07-30
DE2322532A1 (de) 1973-11-22
IE37596B1 (en) 1977-08-31
ES414411A1 (es) 1976-02-01

Similar Documents

Publication Publication Date Title
FR2183792B1 (en:Method)
JPS5614684B2 (en:Method)
JPS505458A (en:Method)
JPS4971213A (en:Method)
JPS4932422U (en:Method)
JPS495343U (en:Method)
JPS4928972A (en:Method)
JPS4987735U (en:Method)
FR2170353A5 (en:Method)
JPS4925851U (en:Method)
JPS4890131A (en:Method)
JPS4913167Y1 (en:Method)
JPS4912767A (en:Method)
FR2192997A1 (en:Method)
FR2192995A2 (en:Method)
CS158723B2 (en:Method)
SE7106888L (en:Method)
CH561961A5 (en:Method)
CH566178A5 (en:Method)
CH565539A5 (en:Method)
CH565100A5 (en:Method)
BG18070A1 (en:Method)
PL78446B1 (en:Method)
CH565085A5 (en:Method)
CH569152A5 (en:Method)